Huntington Disease Clinical Trial
Official title:
Accelerated Diffusion MRI as a Potential Image Based Biomarker for Hungtington Disease
The hypotheses of the project are
1. Diffusion MRI using compressed sensing could have reduced motion sensitivity and
improved susceptibility related artifact because of accelerated acquisition.
2. The macromolecule deposition in the brain of patients with Huntington Disease (HD) can
lead to changes detectible by diffusion MRI.
To validate the hypothesis that the new accelerated diffusion MRI technique could produce a
new biomarker for HD, patients with Huntington Disease will be recruited. The diffusion index
will be calculated using accelerated acquisition. The diagnostic performance will be
evaluated for data reconstructed with and without acceleration. The correlation with the
disease severity will be assessed.
Diffusion magnetic resonance imaging has emerged as a sensitive, noninvasive tool for
assessing the abnormalities in the central nervous system. Applications have been reported in
many neurological disorders. However, because of the motion-sensitizing diffusion gradient
and the prolonged diffusion encoding time, clinical practice could be difficult especially in
patients with motor disorders such as Huntington Disease. Currently there existed no useful
biomarker which could reflect either the disease progression or severity of Huntington
disease. There is a growing interest in imaging Huntington disease using diffusion magnetic
resonance imaging because of its capability to depict the micro-environmental changes.
Unfortunately the excessive motor abnormality such as chorea yields the acquisition of
diffusion magnetic resonance imaging unfeasible in a clinical setting. The diffusion MRI with
compressed sensing demonstrated reduced motion sensitivity and improved susceptibility
related artifact because of the accelerated acquisition. Because of the reduced acquisition
time, diffusion MRI in patient with Huntington Disease would be possible. It is therefore
expected that the macromolecule deposition in the brain of patients with HD can lead to
detectible changes in diffusion properties. The accelerated diffusion MRI techniques will be
used to acquire data from healthy volunteers and patients with Huntington disease. The aim of
the study is to develop and optimize a novel accelerated diffusion Magnetic Resonance Imaging
(MRI) technique using advanced compressed sensing techniques. The joint sparsity constraint
algorithm will be implemented in an in-line reconstruction platform for the diffusion MRI
processing.
The second aim is to test the efficiency of the new accelerated diffusion MRI technique from
phantom and in healthy human. Finally to validate the hypothesis that the new accelerated
diffusion MRI technique could produce a new biomarker for HD, patients with Huntington
Disease will be recruited. The diffusion index will be calculated using accelerated
acquisition. The diagnostic performance will be evaluated for data reconstructed with and
without acceleration. The correlation with the disease severity will be assessed. A risk
management report will be concluded at the end of project execution for registration in the
department of health. The acceleration diffusion MRI could provide new insight to the
etiology of the disease. The in-line image reconstruction platform could be used for
pediatric or psychiatric patients who cannot hold still in the scanner for a prolonged period
and in patients with movement disorders.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Not yet recruiting |
NCT04429230 -
Non-invasive Brain Stimulation in Huntington's Disease
|
N/A | |
Recruiting |
NCT05032196 -
Study of WVE-003 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT03599076 -
Wearable Sensors for Quantitative Assessment of Motor Impairment in Huntington's Disease Huntington's Disease
|
||
Terminated |
NCT04617860 -
Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT05748288 -
Development of the Virtual Unified Huntington's Disease Rating Scale
|
||
Not yet recruiting |
NCT05360082 -
Comparison Between [11C]UCB-J and [18F]SynVest-1 PET in HD.
|
||
Not yet recruiting |
NCT04370470 -
Development of Assessments for Later Stage HD
|
||
Recruiting |
NCT01834053 -
Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.
|
Phase 1/Phase 2 | |
Completed |
NCT01458470 -
A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease
|
Phase 2 | |
Completed |
NCT01357681 -
Effects of EGCG (Epigallocatechin Gallate) in Huntington's Disease (ETON-Study)
|
Phase 2 | |
Completed |
NCT00980694 -
Bioavailability of Ubiquinol in Huntington Disease
|
Phase 1 | |
Completed |
NCT00146211 -
TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease
|
Phase 3 | |
Recruiting |
NCT01412125 -
Study of Biomarkers That Predict the Evolution of Huntington's Disease
|
N/A | |
Completed |
NCT00075140 -
Family Health After Predictive Huntington Disease (HD) Testing
|
Phase 3 | |
Recruiting |
NCT04818060 -
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
|
||
Active, not recruiting |
NCT04698551 -
NIPD on cffDNA for Triplet Repeat Diseases
|
||
Not yet recruiting |
NCT04301726 -
Efficacy of Deutetrabenazine to Control Symptoms of Dysphagia Associated With HD
|
Phase 1 | |
Completed |
NCT03421327 -
Genetic Risk: Whether, When, and How to Tell Adolescents
|
||
Recruiting |
NCT03296176 -
Metabolomic Study in Huntington's Disease (METABO-HD)
|
N/A |